A total of 75 patients underwent sibling allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia in first chronic phase from 1984 to 2000. Of these patients, 51 (68%) were alive at a median follow-up of 98 months (range 34-217 months). Nine (18%) patients relapsed and seven (14%) received donor lymphocyte transfusions. Quality of life (QoL) was assessed crosssectionally using the EORTC QLQ-C30, a Leukaemia-BMT-specific module and questionnaires on sexual functioning, fertility and late effects. A total of 46 (90%) replied. Scores for Role (P ¼ 0.018) and Cognitive (Po0.001) function were significantly lower when compared to an age-adjusted general population. Dyspnoea (P ¼ 0.022) and Financial Difficulties (Po0.001) were significantly more common in the SCT group. No difference was found for scores in the Physical, Emotional and Social domains or the overall Global Health Status/ QoL. Decreased sexual functioning was found in one-third of respondents. Although most BMT recipients reported a good QoL, a minority have difficulty with reintegration into professional roles and consequent monetary problems. Identified cognitive and sexual impairments highlight the need for long-term access to psychosocial support.
Health-related quality of life (QoL) has been defined as referring 'to the extent to which one's usual or expected physical, emotional and social well-being are affected by a medical condition or its treatment'. 3 Most of the previous studies are cross-sectional in design, apply one of several available instruments and pool all patients transplanted for different diagnoses at a single centre. [4] [5] [6] [7] [8] [9] [10] [11] [12] Although marked morbidity in the first few years is evident, there is a clear trend to improved QoL in long-term survivors of transplantation. 6, 8 Nonetheless, aggregated studies confirm that a minority of individuals continue to suffer from the effects of chronic graft-versus-host disease (GvHD) and sexual dysfunction. Our observations confirm and extend those of Kiss et al 12 in a group of 24 patients receiving SCT for CML in first CP.
The European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaire -QLQ-C30 13 was used in this study. Both EORTC population reference data and CML-specific data have been generated using this instrument. [14] [15] [16] In addition to the generic questionnaire, a transplantation-specific module has been designed and has been incorporated in previous assessments of QoL in similar populations. 17 The aims of this study were to measure long-term QoL post-SCT for CML and to compare these results with those of a general population. EORTC QLQ-C30 data have also been collected from participants in the MRC CML 3 randomised trial on the use of interferon in CML. By identifying areas of reduced functioning, we hoped to increase awareness of psychosocial issues requiring attention in SCT Late Effects clinics.
Patients and methods

Study design and patient population
This is a retrospective analysis of 75 consecutive patients who underwent HLA-matched sibling bone marrow (BM; n ¼ 68) or peripheral blood stem cell (PBSC; n ¼ 7) SCT for CML in first CP between November 1984 and February 2000 at the National Bone Marrow Transplant Centre at St James's Hospital in Dublin (Ireland). The diagnosis was confirmed by the identification of the t(9;22) translocation (Philadelphia chromosome) on marrow metaphases in all patients. HLA typing for HLA-A, -B and -DR alleles consisted of either standard microcytotoxicity assays or, more recently, molecular typing. All but one patient, who had moved to another country, were followed at the Late Effects Clinic at the same institution and evaluated by one of three of the authors (EV, JO'R or SMcC). Medical data were collected by chart review and from the hospital Information Management System (IMS). Of 51 surviving patients, 46 (90%) responded to the QoL questionnaire (see Appendix A1), which was simultaneously sent to all survivors by post in 2003.
Transplantation procedure
In vitro T-cell depletion was performed in nine (12%) BM sibling allograft procedures between 1986 and 1990. One subsequent patient underwent in vivo T-cell depletion with alemtuzumab (Campath & ). In the remaining cases, the stem cell source was either unmanipulated BM (n ¼ 58) (78%) or mobilised PBSCs (n ¼ 7) (9%).
Two conditioning regimens were in use during this period. A total of 24 (32%) patients received cyclophosphamide (60 mg/kg) intravenously on days À2 and À1 followed by total body irradiation (TBI 9.5 Gy (1984-1988), 7.5 Gy (1989 7.5 Gy ( -2000 ) in a single fraction on day 0. A total of 51 (68%) patients received busulphan (1 mg/kg q.d.s. PO) on days À6 to À3 and cyclophosphamide (60 mg/ kg) on days À2 and À1. Donor-recipient ABO incompatibility was managed by plasmapheresis of the recipient or red cell depletion of donor BM.
GvHD prophylaxis and treatment
Between 1984 and 1992, 10 (13%) patients received T-celldepleted transplants, and GvHD prophylaxis consisted of cyclosporin alone. Since 1992, patients received cyclosporin and methotrexate according to the Seattle protocol. 18 Cyclosporin was tapered from day 100 in the absence of GvHD and stopped at day 180. Acute GvHD was confirmed on biopsy and graded according to conventional criteria. 19 Treatment for acute GvHD of grade II or greater consisted of high-dose methylprednisolone (1 g/m 2 /day i.v.). Chronic GvHD was classified as limited or extensive and treated with corticosteroids, cyclosporin, tacrolimus or mycophenolate mofetil, or a combination of these agents, as deemed appropriate.
Long-term follow-up
Patients were seen at least annually at the Late Effects Clinic at St James's Hospital. This consisted of physical assessment, haematological and biochemical panels and immunological and endocrinological panels, including sex hormones.
QoL assessment
The QoL study was prospectively approved by the institutional Joint Research Ethics Committee. The questionnaires were sent by post. The self-administered questionnaire consisted of the following: the EORTC QLQ-C30 (version 3), a Leukaemia-BMT-specific module and a short section on sexual functioning, fertility and late effects of SCT (see Appendix A1). The EORTC QLQ-C30 (v. 3), a cross-culturally validated questionnaire, is a generic QoL tool made up of 30 questions that have been chosen to cover symptoms common to a wide range of cancers. 13 It includes five multi-item functional scales (Physical, Role, Emotional, Cognitive and Social Functioning) in the QLQ-30 (v. 3), and a combined Global Health Status/QoL scale. The reliability and validity of the EORTC QLQ-C30 have been confirmed in previous studies. 11, 13, 20 High internal consistency and reliability has also been demonstrated in a BMT population. 6 The Leukaemia-BMT (QLQ-LEU) module was developed to evaluate the long-term sequelae of leukaemia treatments. 21 It is a 32-item questionnaire that was designed to be sensitive to GvHD and an increased susceptibility to infection. It has been validated in two international leukaemia trials. 22 The questions on sexual functioning were consistent with guidelines from the Diagnostic and Statistical Manual for Mental Disorders (DSM IV) according to which sexual dysfunction is divided into problems of sexual drive (interest), sexual arousal, orgasm disorder and pain disorders (eg dyspareunia, vaginismus). They have been described previously. 22, 23 The four questions asked about: (1) sexual interest, (2) activity, (3) pleasure and (4) ability on a three-way scale (increased, unchanged or decreased). One question on the Leukaemia-BMT (QLQ-LEU) module also dealt with pain during sexual intercourse.
The degree to which they were bothered by infertility was assessed on a 7-point rating scale, which ranged from 'not at all' to 'very much'. Patients who considered themselves infertile as a result of SCT were asked if they had or intended to pursue alternative options (adoption, artificial reproductive techniques). Those who had done so were then asked whether this had been successful.
Statistical methods
Categorical data are presented as percentages. The median and range of values are given for continuous data. The outcome variables for all patients transplanted were survival, leukaemia-free survival, current leukaemia-free survival, transplant-related mortality and relapse. Survival was calculated from the date of transplant. Leukaemia-free survival was defined as survival without cytogenetic and/or molecular evidence of leukaemia in either the marrow or peripheral blood. These outcomes were calculated using the method of Craddock et al. 24 Analysis of the EORTC QLQ-C30 data and the leukaemia-specific module was performed using SPSS software. The results of the QLQ-C30 (v. 3) have been compared with data from a large reference population. As expected, the QoL scores were not normally distributed.
Statistical comparisons have therefore been made between the proportions of respondents in each group falling into the highest-scoring category (best function) against all other categories in the functional scales or the lowestscoring category (least symptoms) against all other categories in the symptom scales.
The mean and standard deviation (s.d.) scores were also calculated to allow for the results from the BMT population to be shown alongside those from patients with CP CML in both arms of the MRC CML3 study on the long-term use of interferon. 16 Though these data are nonnormally distributed, nonparametric methods for statistical comparisons could not be performed due to lack of availability of the original CML3 data.
Significance at Po0.05 is assumed throughout.
Results
Clinical outcome
Overall (68%), leukaemia-free (55%) and current leukaemia-free survival (64%) are shown in Figure 1 . The questionnaire was sent to all survivors of SCT (n ¼ 51).
The demographic data for the SCT group (n ¼ 75) were comparable to this cohort (Table 1) . EBMT scores are provided. 25 A total of 15 patients (20%) relapsed at a median of 25 months (range 6-122 months) after SCT. Three patients relapsed and died of progressive disease. Of the 12 subsequent relapses, 10 were treated with donor lymphocyte transfusions (DLTs). Seven are alive at a median of 69 months (range 41-117 months). Two patients were treated with imatinib.
Two (4%) patients developed secondary malignancies. A high-grade EBV-associated laryngeal non-Hodgkin's lymphoma (NHL) was diagnosed 6 years post transplant in a male patient who had received a T-cell-depleted SCT and was successfully treated with conventional CHOP chemotherapy. 26 A haematological relapse of CML occurred 2 years later, which responded to DLT. He is currently well . For OS and LFS, patients were censored at the time of death and disease relapse, respectively. For CLFS, patients who had relapsed and who had returned to a disease-free state by cytogenetic or molecular analysis were included in the CLFS cohort at the time that these methods confirmed the absence of disease. and in molecular remission 17 years following his original transplant. Breast cancer was diagnosed in a female patient 5 years post-allograft. She had a mastectomy followed by chemotherapy and is currently well. In all, 11 (22%) patients developed cataracts, 10 (91%) of whom have been successfully treated. A total of 16 female patients (80% of total female population) are on hormone replacement therapy (HRT). Eight patients (16%) have developed overt or compensated primary hypothyroidism and are on replacement therapy with L-thyroxine.
GvHD
The rate of acute GvHD (of grade II or greater) for all SCT recipients was 37%. The rate was 26% in our cohort. The rates of localised and extensive chronic GvHD for the group as a whole are 17 and 17% respectively and 26 and 22% respectively for our cohort.
QoL assessment
The results of the QLQ-C30 (v. 3) have been compared with data from a large reference population. Figure 2a Scores for the Leukaemia-specific module, QLQ-LEU, are shown in Table 2 . There were five symptoms that more than 10% of respondents considered problematic ('Quite a bit' or 'very much') in the standard 4-point Likert scales. These were Mouth Dryness (13%), Eye Dryness (21%), Blurred Vision (13%), Cough (33%) and Hair Loss (13%).
The mean and s.d. scores from two CML patient groups in the CML MRC3 study, which examined the long-term effects of interferon on QoL, are shown alongside our results in Table 3 .
Sexuality-fertility
The results of the sexuality-fertility module are shown in Table 4 . The instructions for these questions asked patients to indicate what changes they had experienced since treatment. The four aspects of sexual functioning remained the same for 62-67% of the sample. Sexual activity showed the greatest decrease, with 38% of subjects reporting decreased activity.
When asked about infertility, 59% reported that they were infertile, 26% did not know and 7% said they were not infertile. A total of 83% said they were aware of infertility being a consequence of treatment. The remainder failed to answer this question. Seven subjects (15%) were looking for a substitute (eg adoption, assisted reproductive techniques). Subjects were asked to rate how much they were bothered by infertility on a scale of 1-7 (1 being not at all and 7 being very much). Almost half the respondents (48%) were not bothered by infertility, while 15% were very bothered by it (score of 7). The remainder were distributed along the scale.
Discussion
The long-term survival rates for patients who have received sibling SCTs for CML have improved incrementally in the last 20 years. A major contribution to improved outcome in CML following SCT has been the ability to treat successfully disease relapse with DLT. 27 In our cohort, 51 (68%) patients were alive and eligible for participation in this QoL study at a median follow-up of 98 months from SCT.
A previous prospective longitudinal study at our centre revealed physical, psychological and social functioning to be most impaired at 3 months post-SCT and that it was only in the last few months of the year following transplant The four questions asked about: (1) sexual interest, (2) activity, (3) pleasure and (4) ability on a three-way scale (increased, unchanged or decreased) and are consistent with guidelines from the Diagnostic and Statistical Manual for Mental Disorders (DSM IV). 22, 23 that psychological well-being began to recover. 28 In a prospective study of Health-related QoL using the EORTC QLQ-C30, the physical, role and social functioning of allograft recipients were still found to be significantly impaired at 1 year compared with the general population. 29 However, QoL was reported as good to excellent by almost 90% of 53 BMT survivors at 3 years. 30 Sutherland et al 31 noted that patients who survived more than 3 years post transplant were indistinguishable from the normal population in most domains and significantly better in certain psychosocial aspects of health. This cross-sectional study at a median of over 8 years post transplant found that, when compared to an ageadjusted reference population, a significantly lower proportion of transplanted patients had scores in the highest category in the role and cognitive domains. In a study of 98 patients in continued complete remission after treatment for AML with either BMT (allogeneic or autologous) or chemotherapy, reduced role functioning (eg 'are you limited in any way in doing either your work or doing household jobs?') was more frequently seen after allogeneic BMT and, to a lesser degree, after autologous BMT, than after chemotherapy. 22 Reintegration into professional life can be difficult. 8 Problems with finance are common 32, 33 and may partially reflect this failure to return to full-time employment. A significantly higher percentage of long-term survivors in our study (35 vs 15%) reported financial difficulties compared to the general population. Our unit policy is to have social workers meet with all patients to ensure familiarity with national social welfare entitlements. Counselling and written information are also available in an outpatient setting. Clinic patients have highlighted high mortgage insurance premiums as an issue. The provision of information to insurance companies regarding the excellent long-term survival rates for patients transplanted for CML may be of benefit. 33 Over 20% of long-term survivors (410 years) of transplantation for CML have reported poor memory to be bothersome. 12 In our study, the largest difference between respondents and the general population was noted for cognitive functioning, with only 61% of the SCT population in the highest-scoring category in this domain. An association with total dose of TBI has been postulated. TBI-related cognitive impairment has previously been reported to involve slowed reaction time, reduced attention and concentration, and difficulties in reasoning and problem-solving. 34 We did not find a higher rate of cognitive impairment among the third of our respondents who received conditioning including TBI, although analysis is limited due to group size. No association between impaired cognition and age at SCT was evident, although Bush et al 6 previously found that poorer overall cognitive function reflected increasing recipient age at the time of transplant.
The MRC CML 3 trial used the EORTC QLQ-C30 questionnaire to assess the effects of interferon on QoL in a CML population. 16 Although no formal statistical comparisons were possible, it is noteworthy that the BMT population had higher mean scores on all five functional scales and on the aggregated global health status/QoL scale than the group taking interferon. When compared to the CML group not taking interferon, the BMT population had higher mean scores on the physical, role and emotional scales and also on the aggregated global health status/QoL scale.
Chronic GvHD is the major determinant of QoL post transplantation. 7, 10, 11 The incidence of cGvHD after sibling-matched SCT is between 27 and 50%. 35 Overall, chronic GvHD was diagnosed at some point in 24 (48%) of our surviving patients, 11 (22%) with extensive and 13 (26%) with localised disease. At a median follow-up of over 8 years, only four (8%) patients were receiving systemic immunosuppression to treat cGvHD. Although 13 and 21% of respondents reported problematic dryness of the mouth and eyes respectively in the QLQ-LEU module, the low symptom scores for the group as a whole reflect the low level of active cGvHD in our sample. Although dyspnoea was significantly more common among BMT survivors, aggregated scores for physical function were similar to the general population values. This is in distinction to studies with higher rates of active cGvHD, which have reported impaired physical performance as the predominant component of reduced QoL scores post transplant. 7, 22 The adverse impact of transplantation on sexual functioning is almost a universal finding. [5] [6] [7] [8] [9] 22 Our data revealed decreased sexual functioning in between 33 and 38% of respondents. More of the younger age group (o35 years at transplant) had the same or increased level of sexual activity post transplant compared to the older group (P ¼ 0.023). Wingard et al 36 found younger age at transplant to be associated with a greater likelihood of sexual satisfaction post-SCT. Regardless of age, the likelihood of a short-term decrease in libido post transplant should be discussed with the patient and sexual partner. Patients also benefit from discussion of sexuality in the post transplant period. 37 As transplant clinicians may either be uncomfortable or untrained for this task, resources should be identified to allow for referrals as needed. Gonadotrophin levels should be monitored so that pharmacological intervention can be instituted when appropriate.
Discussion of the likelihood of gonadal failure and options for sperm and/or embryo cryopreservation should take place at the time of diagnosis. Although patients in our unit are counselled by consultant haematologists and provided with written information, recall is frequently poor. 27 Seven (15%) patients gave the maximum score to describe how seriously infertility has affected their lives. Reactive depression is possible in this setting and counselling should be made available. In addition, seven patients (15%) were actively pursuing either adoption or assisted reproductive techniques.
When 172 adults at a median follow-up of 43.5 months after SCT were asked whether they had 'returned to normal', only 48% answered unequivocally in the positive. 38 Bush et al, 6 however, found that 74% of long-term survivors rated their QoL as being as good as or better than prior to transplantation. Such a question may, however, be generating misleading responses. Smith et al 39 have found that QoL is the subjective appraisal of one's current life based primarily on psychological functioning and to a lesser extent on physical functioning. In this light, it is less surprising that, despite a low level of persistent symptomatology, the self-reported ratings for overall Global Health Status/QoL did not differ significantly from the general population values. One postulated explanation for this psychological adjustment is that the life-threatening nature of transplantation imposes an 'existential re-evaluation' where the 'comparative anchor is no longer perfect health'. 28 As a theoretical framework, an adaptation level theory has been advanced whereby patients adapt to disease and treatment demands with the passage of time by adjusting their perceptions of normality to fit current circumstances or expectations. 40 This interpretation provides an explanation for this recurrent apparent discrepancy whereby post-BMT patients appear to minimise the effects of mild to moderate symptomatology when assessing their overall QoL.
We report the largest study to date of QoL after sibling SCT for CML in first CP. All the patients were assessed by three of the authors in the same institution, which may have contributed to the high response rate to the questionnaire (90%). The low rate of active cGvHD was reflected in the relatively normal scores for physical function. Impaired role function and related financial difficulties, however, continue to be a problem. The identification of late cognitive deficits suggests the need for more formal neuropsychological evaluation and support for adult BMT recipients. The psychosexual problems and degree of confusion and concern regarding fertility highlight the need for the creation of a dedicated liaison service for these issues.
Patients sometimes report that they have some of the following symptoms.This time we would like to know whether you have experienced any of these symptoms during the past month. 
